Stock listing
HKEX:1521 Frontage Holdings Corp. (方達控股) 股價
Home listing (HKEX) of Frontage Holdings Corp.
Follow Frontage Holdings Corp. into a list and get an email when it puts out news.
Share price · HKEX:1521
$2.08 HKD -0.00 (-0.2%)
Close on Nov 20, 2026
- Day range
- $2.07 – $2.08 HKDNov 20, 2026
- Volume
- 762,000 sharesNov 20, 2026
- Market cap
- $4.23B HKDAt the close on Nov 20, 2026 · price × 2.03B shares outstanding
- 52-week range
- $0.68 – $2.22 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.34M HKDMedian day 84,000 shares · 17 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:1521 · Home | $2.08 HKD | -0.005 (-0.2%) | 762,000 | $2.075 | $2.08 | $2.07 | $2.085 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:1521 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.08 | -0.005 | -0.2% | $2.075 | $2.08 | $2.07 | 762,000 | |
| $2.085 | +0.005 | +0.2% | $2.075 | $2.09 | $2.065 | 1,054,000 | |
| $2.08 | +0.015 | +0.7% | $2.06 | $2.09 | $2.06 | 2,340,000 | |
| $2.065 | -0.01 | -0.5% | $2.08 | $2.08 | $2.06 | 1,516,000 | |
| $2.075 | -0.01 | -0.5% | $2.08 | $2.08 | $2.055 | 3,112,000 | |
| $2.085 | -0.01 | -0.5% | $2.085 | $2.09 | $2.07 | 3,826,708 | |
| $2.095 | -0.03 | -1.4% | $2.12 | $2.12 | $2.075 | 12,496,000 | |
| $2.125 | +0.635 | +42.6% | $2.21 | $2.22 | $2.055 | 38,131,594 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | 0.00 | 0.0% | $1.49 | $1.49 | $1.49 | 0 | |
| $1.49 | +0.175 | +13.3% | $1.36 | $1.50 | $1.335 | 4,282,000 | |
| $1.315 | +0.175 | +15.4% | $1.13 | $1.355 | $1.13 | 1,408,000 | |
| $1.14 | +0.035 | +3.2% | $1.15 | $1.16 | $1.12 | 188,000 | |
| $1.105 | -0.03 | -2.6% | $1.13 | $1.155 | $1.095 | 318,000 | |
| $1.135 | +0.035 | +3.2% | $1.13 | $1.15 | $1.10 | 186,000 | |
| $1.10 | -0.01 | -0.9% | $1.11 | $1.11 | $1.05 | 294,000 | |
| $1.11 | +0.005 | +0.5% | $1.105 | $1.11 | $1.105 | 126,000 | |
| $1.105 | -0.055 | -4.7% | $1.15 | $1.15 | $1.10 | 326,000 | |
| $1.16 | +0.01 | +0.9% | $1.16 | $1.16 | $1.16 | 8,000 | |
| $1.15 | 0.00 | 0.0% | $1.15 | $1.15 | $1.15 | 0 | |
| $1.15 | 0.00 | 0.0% | $1.15 | $1.15 | $1.15 | 0 | |
| $1.15 | -0.03 | -2.5% | $1.075 | $1.15 | $1.075 | 6,000 | |
| $1.18 | 0.00 | 0.0% | $1.18 | $1.18 | $1.18 | 0 | |
| $1.18 | 0.00 | 0.0% | $1.19 | $1.19 | $1.18 | 12,000 | |
| $1.18 | +0.06 | +5.4% | $1.185 | $1.185 | $1.18 | 4,000 | |
| $1.12 | +0.015 | +1.4% | $1.12 | $1.125 | $1.12 | 84,000 | |
| $1.105 | 0.00 | 0.0% | $1.105 | $1.105 | $1.105 | 0 | |
| $1.105 | +0.025 | +2.3% | $1.10 | $1.105 | $1.10 | 12,000 | |
| $1.08 | 0.00 | 0.0% | $1.08 | $1.08 | $1.08 | 0 | |
| $1.08 | -0.005 | -0.5% | $1.08 | $1.11 | $1.08 | 288,000 | |
| $1.085 | +0.055 | +5.3% | $1.085 | $1.085 | $1.085 | 2,000 | |
| $1.03 | -0.03 | -2.8% | $1.03 | $1.06 | $1.03 | 68,000 | |
| $1.06 | -0.03 | -2.8% | $1.08 | $1.08 | $1.025 | 154,000 | |
| $1.09 | 0.00 | 0.0% | $1.09 | $1.09 | $1.09 | 56,000 | |
| $1.09 | -0.01 | -0.9% | $1.10 | $1.10 | $1.09 | 8,000 | |
| $1.10 | -0.10 | -8.3% | $1.04 | $1.20 | $1.04 | 364,000 | |
| $1.20 | +0.02 | +1.7% | $1.20 | $1.20 | $1.07 | 30,000 | |
| $1.18 | 0.00 | 0.0% | $1.20 | $1.20 | $1.18 | 26,000 | |
| $1.18 | -0.08 | -6.3% | $1.20 | $1.20 | $1.18 | 26,000 | |
| $1.26 | +0.06 | +5.0% | $1.20 | $1.285 | $1.155 | 364,000 | |
| $1.20 | -0.095 | -7.3% | $1.24 | $1.24 | $1.19 | 144,000 | |
| $1.295 | -0.005 | -0.4% | $1.29 | $1.295 | $1.29 | 128,000 | |
| $1.30 | +0.04 | +3.2% | $1.27 | $1.30 | $1.26 | 86,000 | |
| $1.26 | +0.05 | +4.1% | $1.29 | $1.29 | $1.24 | 24,000 | |
| $1.21 | +0.01 | +0.8% | $1.205 | $1.21 | $1.205 | 30,000 | |
| $1.20 | 0.00 | 0.0% | $1.20 | $1.20 | $1.17 | 226,000 | |
| $1.20 | -0.01 | -0.8% | $1.21 | $1.21 | $1.20 | 102,000 | |
| $1.21 | +0.005 | +0.4% | $1.20 | $1.21 | $1.165 | 206,000 | |
| $1.205 | -0.01 | -0.8% | $1.215 | $1.25 | $1.205 | 140,000 | |
| $1.215 | -0.015 | -1.2% | $1.24 | $1.25 | $1.16 | 122,000 | |
| $1.23 | -0.06 | -4.7% | $1.29 | $1.29 | $1.22 | 412,000 | |
| $1.29 | +0.04 | +3.2% | $1.27 | $1.32 | $1.27 | 232,000 | |
| $1.25 | -0.015 | -1.2% | $1.24 | $1.265 | $1.24 | 152,000 |
- Ticker
- HKEX:1521
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 20, 2026
Disclosure of Dealings under Rule 22 of the Takeovers Code
Latest deck · December 2025
Investor Presentation (December 2025)
Investor deck · 37 slides
Latest news
Progress announcement audited financial information for the six months ended June 30, 2026
Nov 17, 2026
Closed $2.09 (+0.2%) on Nov 18, 2026
Exchange notice - resumption of trading
Nov 9, 2026
Closed $2.13 (+42.6%) on Nov 10, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Nov 4, 2026
Closed $1.49 (0.0%) on Nov 5, 2026
Announcement unaudited financial information for the third quarter of 2026
Oct 29, 2026
Closed $1.49 (0.0%) on Oct 30, 2026
Trading halt
Oct 21, 2026
Closed $1.49 (0.0%) on Oct 22, 2026
Exchange notice - trading halt
Oct 21, 2026
Closed $1.49 (0.0%) on Oct 22, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Oct 6, 2026
Closed $1.15 (0.0%) on Oct 7, 2026
Notification Letter and Request Form for Non-Registered Shareholders
Sep 22, 2026
Closed $1.08 (0.0%) on Sep 23, 2026
Frontage Holdings Corp. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 19 in the last 12 months · 23 in all · newest Nov 20, 2026 · oldest 2024
- Decks
- 11 decks · latest December 2025
Where Frontage Holdings Corp. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:1521 方達控股 · Home listing · This page | HKEX | Hong Kong | HKD |
| OTC:FGHQF | OTC | United States | USD |
Valuation
P/E 79.5× against a median of 32.0×: the highest of 4 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $5.04B HKD
- P/E
- 79.5×
- EV/sales
- 2.5×
- EV/EBITDA
- 12.6×
- Price/book
- 1.5×
- Gross margin
- 27.0%
- Operating margin
- 6.3%
- Net margin
- 2.6%
- Debt to equity
- 0.4×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Frontage Holdings Corp. · HKEX:1521 | US$539.7M | US$643.1M | 79.5× | 2.5× | 12.6× | 1.5× | 2.6% | 0.4× | n/a |
| Getein Biotech, Inc. Class A · SSE:603387 | US$608.2M | US$358.4M | 13.8× | 2.1× | n/a | 1.4× | 26.3% | 0.0× | n/a |
| QuidelOrtho Corporation · NASDAQ:QDEL | US$570.9M | US$828.9M | n/a | 0.3× | 2.5× | 0.3× | −14.2% | 0.2× | 2.56 |
| Shanghai Obio Technology (Group) Corp., Ltd. Class A · SSE:688238 | US$542.6M | US$548.0M | n/a | 12.4× | n/a | 2.9× | −74.6% | 0.5× | n/a |
| Boji Medical Technology Co., Ltd Class A · SZSE:300404 | US$524.0M | US$473.9M | 60.3× | 3.1× | n/a | 3.2× | 5.7% | 0.0× | n/a |
| Myriad Genetics, Inc. · NASDAQ:MYGN | US$523.7M | US$537.7M | n/a | 0.7× | n/a | 1.9× | −16.1% | 0.5× | 0.67 |
| Pacific Biosciences of California, Inc. · NASDAQ:PACB | US$510.1M | US$953.7M | n/a | 5.9× | n/a | n/a | −81.3% | n/a | 2.13 |
| MedicalSystem Biotechnology Co., Ltd. Class A · SZSE:300439 | US$482.2M | US$330.3M | 32.0× | 1.3× | n/a | 1.1× | 6.0% | 0.0× | n/a |
| Alpha Teknova, Inc. · NASDAQ:TKNO | US$480.0M | US$476.7M | n/a | 10.4× | n/a | 8.0× | −34.8% | 0.2× | 1.01 |
| Zhejiang Orient Gene Biotech Co., Ltd. Class A · SSE:688298 | US$479.9M | US$158.3M | n/a | 1.1× | n/a | 0.6× | −64.5% | 0.0× | n/a |
| Assure Tech (Hangzhou) Co. Ltd. Class A · SSE:688075 | US$479.0M | US$282.6M | n/a | 4.5× | n/a | 0.6× | −5.1% | 0.0× | n/a |
| Median of the others | US$516.9M | US$475.3M | 32.0× | 2.6× | 2.5× | 1.4× | −15.2% | 0.0× | 1.57 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.11 HKD · Analysts' mean
- EPS, year to Dec 2026
- 0.012 · 1 analyst
- Revenue, year to Dec 2026
- 297.5M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John Lin | Co-Chief Executive Officer |
| Wentao Zhang | Co-Chief Executive Officer |
| Huan Wang | Interim Chief Financial Officer |
| Dongmei Wang | Executive Vice President, Global Sales & Marketing |
| Suden Rao | Senior Vice President, Human Resources, North America |
| Abdul Mutlib | Chief Scientific and Strategy Officer, and President Canada |
| Song Li | Executive Chairman, Board of Directors |
Board
| Director | Role |
|---|---|
| Jingsong Wang | Chairman |
| Song Li | Executive Chairman, Board of Directors |
| Yifan Li | Chairman of the Board |
| Erh Fei Liu | |
| Hao Wu |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 22, 2025 | −0.8% |
| Quarter to Mar 31, 2025 | Apr 24, 2025 | −1.7% |
| Q4 2024 | Mar 27, 2025 | +9.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2025) | Investor deck | 37 slides | December 2025 |
| Fact Sheet (May 2023) | Fact sheet | 2 slides | May 2023 |
| Fact Sheet (May 2023) | Fact sheet | 1 slide | May 2023 |
| Fact Sheet (May 2023) | Fact sheet | 2 slides | May 2023 |
| Fact Sheet (April 2023) | Fact sheet | 2 slides | April 2023 |
| Fact Sheet (September 2022) | Fact sheet | 2 slides | September 2022 |
| Investor Presentation (August 2019) | Investor deck | 22 slides | Aug 1, 2019 |
| Fact Sheet (December 2018) | Fact sheet | 2 slides | December 2018 |
| Fact Sheet (December 2018) | Fact sheet | 2 slides | December 2018 |
| Investor Presentation (May 2017) | Investor deck | 29 slides | May 2017 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Frontage Laboratories — Investor Presentation (March 2010) | Investor deck | 55 slides | Mar 30, 2010 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 256.7M | 254.9M | 259.9M | 250.4M | 184.4M | 125.8M | 100.4M | 83.1M | 70.2M | 48.6M |
| Cost of revenue | 187.5M | 185.1M | 181.5M | 161.2M | 117.7M | 84.3M | 63.1M | 49.2M | 39.2M | 29.4M |
| Gross profit | 69.2M | 69.8M | 78.4M | 89.2M | 66.7M | 41.5M | 37.3M | 33.9M | 31.1M | 19.3M |
| Research and development | 4.30M | 5.59M | 6.04M | 3.88M | 2.43M | 1.84M | 1.53M | 1.69M | 1.30M | 484.0K |
| Selling, general and administrative | 39.2M | 47.0M | 44.6M | 44.4M | 32.7M | 18.8M | 17.9M | 16.8M | 8.29M | 6.52M |
| Operating income | 16.1M | 9.34M | 20.2M | 33.6M | 25.3M | 15.7M | 14.5M | 14.6M | 18.8M | 11.3M |
| Depreciation and amortization | 34.9M | 37.7M | 35.6M | 29.9M | 23.9M | 12.3M | 7.51M | 4.31M | 3.00M | 2.67M |
| EBITDA | 51.0M | 47.0M | 55.8M | 63.4M | 49.2M | 28.0M | 22.1M | 18.9M | 21.8M | 13.9M |
| Interest expense | 7.56M | 9.56M | 7.07M | 3.95M | 2.58M | 2.20M | 1.23M | 378.0K | 315.0K | 272.0K |
| Income before tax | 11.6M | 2.74M | 14.6M | 36.1M | 25.1M | 19.5M | 20.9M | 14.1M | 16.1M | 10.4M |
| Income tax | 4.83M | 2.13M | 3.85M | 10.2M | 6.14M | 2.11M | 2.43M | 2.85M | 5.97M | 3.13M |
| Net income | 6.79M | 791.0K | 10.8M | 25.7M | 18.4M | 17.1M | 18.4M | 11.2M | 10.2M | 6.65M |
| Earnings per share, basic | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 37.0M | 44.1M | 53.2M | 87.4M | 144.6M | 212.1M | 207.8M | 16.3M | 4.34M | 3.25M |
| Short-term investments | 2.85M | 0 | 1.41M | 3.09M | 4.08M | 2.45M | ||||
| Receivables | 89.0M | 81.3M | 70.2M | 64.0M | 46.3M | 30.6M | 24.4M | 24.5M | 23.4M | 12.8M |
| Inventory | 2.98M | 2.88M | 2.80M | 3.19M | 946.0K | 724.0K | 173.0K | 73.0K | 0 | -12.8M |
| Current assets | 138.1M | 137.7M | 141.6M | 171.8M | 211.1M | 254.4M | 242.4M | 44.2M | 30.3M | 17.5M |
| Property, plant and equipment | 168.6M | 180.7M | 183.8M | 180.2M | 146.2M | 82.3M | 49.3M | 22.9M | 14.2M | 12.6M |
| Goodwill | 187.6M | 187.0M | 183.9M | 149.2M | 71.5M | 24.9M | 6.25M | |||
| Total assets | 541.0M | 553.6M | 571.9M | 550.6M | 475.8M | 382.7M | 315.3M | 77.5M | 57.2M | 42.6M |
| Accounts payable | 10.2M | 8.66M | 12.6M | 11.0M | 11.5M | 7.41M | 4.69M | 3.57M | 3.20M | 1.28M |
| Current liabilities | 103.5M | 111.5M | 99.6M | 97.5M | 73.0M | 45.5M | 29.1M | 29.7M | 19.6M | 15.8M |
| Long-term debt | 28.2M | 44.4M | 61.3M | 35.1M | 0 | 0 | 500.0K | 1.17M | 3.00M | |
| Total debt | 127.6M | 154.4M | 145.1M | 118.2M | 57.9M | 40.6M | 20.9M | 6.98M | 10.7M | 7.74M |
| Total liabilities | 191.0M | 219.3M | 226.7M | 214.7M | 152.8M | 93.8M | 50.0M | 33.8M | 27.0M | 23.9M |
| Shareholders' equity | 346.7M | 333.0M | 342.5M | 333.1M | 319.8M | 287.9M | 264.6M | 43.6M | 30.2M | 18.8M |
| Shares outstanding | 2.03B | 2.03B | 2.07B | 2.08B | 2.12B | 2.08B | 1.86B | 2.01B | 2.01B | 2.01B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 43.9M | 40.6M | 39.7M | 62.4M | 44.5M | 31.7M | 18.7M | 22.7M | 6.76M | 9.35M |
| Capital spending | -11.7M | -25.9M | -21.2M | -47.7M | -50.4M | -14.6M | -12.9M | -5.22M | -3.21M | -4.02M |
| Free cash flow | 32.3M | 14.8M | 18.6M | 14.8M | -5.83M | 17.1M | 5.83M | 17.4M | 3.54M | 5.33M |
| Cash from investing | -13.8M | -41.5M | -87.6M | -147.9M | -107.4M | -25.9M | -12.8M | -11.4M | -7.04M | -7.39M |
| Cash from financing | -37.4M | -10.2M | 12.9M | 30.7M | -5.54M | -2.91M | 185.7M | 1.33M | 1.07M | -2.11M |
| Share buybacks | 0 | -11.2M | -4.23M | -8.38M | 2.25M | 3.40M | 204.5M | 49.0K | 0 | 0 |
| Change in cash | -7.79M | -9.10M | -34.2M | -57.2M | -67.5M | 4.33M | 191.4M | 12.0M | 1.08M | -242.0K |
Filings
All 15 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EXCHANGE NOTICE - TRADING HALT | Oct 21, 2026 | Trading halt or suspension | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026 | Oct 6, 2026 | Monthly return | HKEX |
| Notification Letter and Request Form for Non-Registered Shareholders | Sep 22, 2026 | Notification letter | HKEX |
| Notification Letter and Reply Form for Registered Shareholders | Sep 22, 2026 | Notification letter | HKEX |
| 2026 INTERIM REPORT | Sep 22, 2026 | Interim report | HKEX |
Cap table
Built by 6ix from Frontage Holdings Corp.’s releases
- Common shares
- 2,034,078,472
- Fully diluted
- 2,034,078,472
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,034,078,472 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,034,078,472 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Abdul Mutlib | Chief Scientific and Strategy Officer, and President Canada · Since at least Jul 1, 2025 |
| Dongmei Wang | Executive Vice President, Global Sales & Marketing · Since at least Nov 9, 2026 |
| Erh Fei Liu | Director · Since at least Nov 9, 2026 |
| Hao Wu | Director · Since at least Nov 9, 2026 |
| Huan Wang | Interim Chief Financial Officer · Since at least Nov 9, 2026 |
| Jingsong Wang | Chairman · Since at least Nov 9, 2026 |
| John Lin | Co-Chief Executive Officer · Since at least Nov 9, 2026 |
| Song Li | Executive Chairman, Board of Directors · Since at least Jan 15, 2026 |
| Suden Rao | Senior Vice President, Human Resources, North America · Since at least Nov 9, 2026 |
| Wentao Zhang | Co-Chief Executive Officer · Since at least Jul 1, 2025 |
All 11 people
| Person | Seat |
|---|---|
| Yifan Li | Chairman of the Board · Since at least Nov 9, 2026 |
Log in to ask 6ix AI your own questions about Frontage Holdings Corp.